Methods for the costing process in economic evaluation of a rehabilitation programme for patients with chronic lung diseases;Methoden zur Kostenerfassung im Rahmen der okonomischen Evaluation einer Rehabilitations- massnahme bei chronischen Atemwegserkrankungen

Pneumologie

Volumn 54, Issue 7, 2000, Pages 289-295

  Hessel, F P ^a   Wittmann, M ^b   Petro, W ^b   Wasem, J ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Klinik Bad Reichenhall   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; GERMANY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HOSPITAL PATIENT; HUMAN; MEDICAL DOCUMENTATION; MEDICAL TECHNOLOGY; OUTPATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ASTHMA; BRONCHITIS; COSTS AND COST ANALYSIS; FOLLOW-UP STUDIES; GERMANY; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MIDDLE AGED; PILOT PROJECTS; REHABILITATION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 0033861466     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-4455     Document Type: Article

References (20)

1. 1 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1995; 152: S77-120
2. 2 Arbeitsgruppe Reha-Ökonomie des Förderschwerpunktes Rehabilitationswissenschaften. Ökonomische Evaluation in der Rehabilitation. Teil I (Hessel F, Kohlmann T, Krauth C, Nowy R, Seitz R, Siebert U, Wasem J): Prinzipien und Empfehlungen für die Leistungserfassung. Teil II (Burchert H. Hansmeier T, Hessel F, Krauth C, Nowy R, Seitz R, Wasem J): Bewertung der Ressourcenverbräuche. DRV-Schriften Band 1999; 16: 103-246
3. 3 Baladi JF, Menon D, Otten N. Use of economic evaluation guidelines: 2 years experience in Canada. Health Economics 1998; 5: 227-239
4. 4 Canadian Coordinating Office for Health Technology Assessment (CCOHTA). A Guidance Document for the Costing Process. Version 1.0. Canadian Coordinating Office for Health Technology Assessment. 1996
5. nd ed. Canadian Coordinating Office for Health Technology Assessment. 1997
6. 6 Commission of the European Communities. Good clinical practice for trials on medical products in the European community. EEC 111/3976/88-EN. 1990
7. 7 Dranove D. Measuring costs. In: Sloan FA (ed.): Valuing health care. Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge, New York, Melbourne: Cambridge University Press, 1995: 61-76
8. 8 Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press, 1997
9. 9 Gold MR, Siegel JE, Russell LB, Weinstein MC (eds).. Cost-effectiveness in health and medicine. Oxford University Press, 1996
10. 10 Goossens ME, Rutten-van-Molken MP, Kole-Snijders AM, Vlaeyen JW, Van-Breukelen G, Leidl R. Health Economic Assessment of Behavioural Rehabilitation in Chronic Low Back Pain: A Randomized Clinical Trial. Health Economics 1998; 7: 39-51
11. 11 Goossens ME, Rutten-van-Molken MP, Leidl R, Bos SG, Vlaeyen JW, Teeken-Gruben NJ. Cognitive-Educational Treatment of Fibromyalgia: A Randomized Clinical Trial. Economic Evaluation. J Rheumatol 1996; 23: 1246-1254
12. 12 Konsensgruppe "Gesundheitsökonomie". Empfehlungen zur gesundheitsökonomischen Evaluation - Hannoveraner Konsens. Zeitschrift für Allgemeinmedizin 1996; 72: 485-490
13. 13 Koopmanshap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460-466
14. 14 Koopmanschap MA, Rutten FF, van Ineveld B, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1996; 14: 171-189
15. 15 Rutten MP, Postma MJ, Joore MA, Genugten ML, Leidl R, Jager JC. Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respiratory Medicine 1999; 93: 779-787
16. 16 Schulenburg JM, Greiner W, Molitor S, Kielhorn A. Kosten der Asthmatherapie nach Schweregrad. Eine empirische Untersuchung. Medizinische Klinik 1996; 91: 670-676
17. 17 Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Europ Respir J 1999; 13: 281-286
18. 18 Trautner C, Richter B, Berger M. Cost-effectiveness of a structured treatment of asthma. Eur Respir J 1993; 6: 1485-1491
19. 19 Weinstein MC, Siegel JE, Garber AM, Lipscom J, Luce BR, Manning WG, Torrance GW. Productivity costs and health-related quality of life: A response to the Erasmus Group. Health Economics 1997; 6: 505-510
20. 20 Wettengel R, Vollmer WM. Asthma. Medizinische und ökonomische Bedeutung einer Volkskrankheit. Stuttgart, 1994